MichaelTLotzeMD

General Surgery • Pittsburgh, PA

Melanoma

Professor, Surgery, University of Pittsburgh School of Medicine

Join to view full profile

Dr. Lotze is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lotze's full profile

Already have an account?

Office
5117 Centre Ave
# Hillman
Pittsburgh, PA 15213
Phone+1 412-770-9910

Education & Training

University of RochesterResidency, Surgery, 1980 - 1982
University of RochesterResidency, Surgery, 1975 - 1977
Northwestern University The Feinberg School of MedicineClass of 1974

Certifications & Licensure

PA State Medical License 1990 - 2024

Awards, Honors, & Recognition

Fellow (FACS) American College of Surgeons

Clinical Trials

Study of Hydroxychloroquine Before Surgery in Patients With Primary Renal Cell Carcinoma Start of enrollment: 2010 Oct 01
Terminated
Phase 1
Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC) Start of enrollment: 2012 Mar 01
Completed
Phase 1, Phase 2

Publications & Presentations

PubMed

Survey of Changes in Absolute Lymphocyte Counts and Peripheral Immune Repertoire Diversity after External Beam Radiotherapy.
Susannah G Ellsworth, Alison Ross, Kevin R Y Shiue, Pranav Murthy, Miranda L Byrne-Steel
Radiation Research. 2024-12-01
CD28 co-stimulation: novel insights and applications in cancer immunotherapy.
Michael T Lotze, Scott H Olejniczak, Dimitris Skokos
Nature Reviews. Immunology. 2024-12-01
Liquid Biopsy in Pancreatic Ductal Adenocarcinoma: A Review of Methods and Applications.
Genia Dubrovsky, Alison Ross, Pooya Jalali, Michael Lotze
International Journal of Molecular Sciences. 2024-10-13

Press Mentions

ACGT Scientific Advisory Council Chair Michael T. Lotze, MD, Honored with Lifetime Achievement Award from Society for Immunotherapy of CancerNovember 5th, 2021
Chutes & Ladders—Novavax Appoints AstraZeneca Vet Dubovsky to CMO RoleJune 19th, 2020
Boehringer Ingelheim Nabs New US President and CEO; AstraZeneca Vet Hops Aboard Novavax as CMOJune 19th, 2020
Join now to see all

Grant Support

IL-1 Homologues Promote The Acute Inflammatory Response To MelanomaNational Cancer Institute2007–2009
Integrating NK And DC Into Cancer TherapyNational Cancer Institute2005–2009
IL-1 Homologues Promote The Acute Inflammatory ResponseNational Cancer Institute2005–2006
Administrative CoreNational Cancer Institute2005
Apoptotic Pathways Following Chemotherapy Or Gene Therapy Of Oral CancerNational Institute Of Dental &Craniofacial Research1999–2002
Random Evaluation Of Immunization Of Patients With Metastatic MelanomaNational Center For Research Resources1999–2002
Phase 2 Study Of FLT3 Ligand (FLT3) In Metastatic Melanoma PatientsNational Center For Research Resources1999–2002
Immunization For Metastatic Melanoma With Dendritic CellsNational Center For Research Resources1999–2002
Biological Therapeutics ProgramNational Cancer Institute1999–2002
Phase I Melan A/Mart 1 GP100 Trial In Metastatic MelanomaNational Center For Research Resources1998–2002
Dendritic Cell Therapies Elicit Effective Antitumor ResponsesNational Cancer Institute1998–2002
Dendritic Cell Therapy For Hiv--Role Of Cytokines On Enhanced T Cell FunctionNational Institute Of Allergy And Infectious Diseases1998–2001
Oral Carcinoma Treatment--Interleukin 12 And Gene TherapyNational Institute Of Dental &Craniofacial Research1997–2001
Gene Transfection To Enhance Dendritic And Endothelial Cell FunctionNational Cancer Institute1996–2001
Dendritic Cell Biology And TherapyNational Cancer Institute1998–2000
Phase II Study Of FLT3 Ligand In Metastatic Melanoma PatientsNational Center For Research Resources1999
Phase I/II Study Of Immunization In Melanoma Using Dendritic CellsNational Center For Research Resources1999
Clinical Trials Of Biological Response ModifiersNational Cancer Institute1996–1999
Cytokine Gene Therapy Of CancerNational Cancer Institute1995–1999
Biologic Therapy Research Career Development ProgramNational Cancer Institute1997–1998
Dendritic Cells Elicit Effective Antitumor ResponsesNational Cancer Institute1997
Conference On Cellular Immunology Of CancerNational Cancer Institute1997
Phase III Trial To Evaluate The Efficacy Of Recombinant Human GM-CSFNational Center For Research Resources1996–1997
Clinical Trials Of Biological Response ModifiersDivision Of Cancer Treatment1995–1997
Phase I Dose-Escalating Study Of Recombinant Human Interleukin-12National Center For Research Resources1996
Phase I Dose-Escalating Study Of Recombinant Human Interleukin 12National Center For Research Resources1996
In Vivo Testing Of The Immune Response To Tumor MucinNational Center For Research Resources1996
Gene Therapy Of Cancer--Pilot Study Of IL-4 Gene Modified Tumor VaccineNational Center For Research Resources1996
Interleukin 12--Immunology Of A Regulatory CtyokineNational Cancer Institute1995
Locoregional AIT With Autologous IL2 Activated NK CellsNational Cancer Institute1994–1995
Locoregional AIT With Autologous Il2-Activated NK CellsNational Cancer Institute1992–1993
Gene Therapy Of Cancer-Immunological ApproachesNational Cancer Institute1992–1993
T Cell Receptor Usage In Melanoma And Its PrecursorsNational Cancer Institute1992